Table 1 Baseline characteristics, n = 200 patients
From: COVID-19 related deaths in an urban academic medical center in Brooklyn – a descriptive case series
Age in years, median (IQR) | 73 (62–82) |
Breakdown by age group (n, %) | |
≤ 39 | 3 (1·5) |
40–59 | 26 (13) |
60–79 | 107 (53·5) |
80–89 | 49 (24·5) |
> 89 | 15 (7·5) |
Male (n, %) | 117 (58·5) |
Race (n, %) | |
Black | 178 (89) |
Latino | 7 (3·5) |
White | 4 (2) |
Undisclosed | 11 (5·5) |
Origin (n, %) | |
Home | 179 (89·5) |
Nursing home | 21 (10·5) |
Admitted to hospital for reasons other than COVID-19 (n, %) | 11 (5·5) |
Weight | |
TBW, median (IQR), kg | 77.6 (68·55–90·7) |
BMI, median (IQR), kg/m2 | 29 (25·1–32·9) |
Breakdown by BMI (n, %) | |
Underweight (< 18.5) | 4 (2) |
Normal weight (18.5–24.9) | 45 (22·5) |
Overweight (25–29.9) | 68 (34) |
Obese (≥ 30) | 83 (41·5) |
Past Medical History (n, %) | |
Hypertension | 169 (84·5) |
Diabetes mellitus | 115 (57·5) |
Hypertension and diabetes mellitus | 101 (50·5) |
Obesity | 83 (41·5) |
Coronary artery disease | 49 (24·5) |
Chronic kidney disease or end-stage renal disease | 40 (20) |
On hemodialysis prior to admission | 14 (7) |
Cerebral vascular disease | 28 (14) |
Asthma | 16 (8) |
COPD | 17 (8·5) |
History of malignancy | 12 (6) |
HIV-positive | 7 (3·5) |
Renal transplant | 4 (2) |
Known current or former smoker | 19 (9·5) |
History of ACE inhibitor/ARB use | 59 (29·5) |
No known past medical history, not obese | 13 (6·5) |
Number of comorbiditiesa (n, %) | |
No comorbidities | 10 (5) |
1 comorbidity | 28 (14) |
2 comorbidities | 52 (26) |
3 comorbidities | 54 (27) |
4 or more comorbidities | 56 (28) |
More than 1 comorbidity | 162 (81) |
Three or more comorbidities | 110 (55) |